ZNTL - Zentalis Pharmaceuticals drops 30% following ovarian cancer candidate data

Shares of Zentalis Pharmaceuticals (NASDAQ:ZNTL) dropped 30% on Friday after releasing initial phase 1b efficacy data on its candidate, ZN-c3, in combination with chemotherapy in heavily pretreated ovarian cancer patients. ZN-c3, a Wee1 inhibitor, demonstrated an objective response rate ("ORR") of 30.2% across all four combination dose cohorts. The best ORR -- 62.5% -- was seen in the ZN-c3 + paclitaxel cohort. The most commonly reported treatment-related adverse events were nausea (48.2% of patients), neutropenia (41.1%), thrombocytopenia (37.5%), vomiting (30.4%), and anemia (26.8%). Wells Fargo recently initiated Zentalis (ZNTL) with a buy.

For further details see:

Zentalis Pharmaceuticals drops 30% following ovarian cancer candidate data